Home › Therapeutic areas › Oncology › Breast Cancer

Breast Cancer (23 companies)

Companies with an active program in Breast Cancer.

Ticker Company Therapeutic areas Programs Lead stage Mkt cap Programs
AKTS Aktis Oncology Oncology 1 Phase 1 $910M 10
ANIX Anixa Biosciences Oncology 1 Phase 1 $92.8M 3
ARTV Artiva Biotherapeutics Oncology 1 Phase 1 $191M 6
ARVN Arvinas NeurologyOncology Rare 1 Approved $447M 10
BCTX BriaCell Therapeutics Oncology 3 Phase 3 $30.7M 8
CLRB Cellectar Biosciences Oncology 1 Phase 2 $9.2M 7
CMPX Compass Therapeutics Oncology 1 Phase 2 $109M 15
CYDY CytoDyn NeurologyOncology 1 Phase 2 $367M 3
EIKN Eikon Therapeutics Oncology 2 Phase 2 $279M 13
FHTX Foghorn Therapeutics Oncology 1 Preclinical $110M 4
GLSI Greenwich LifeSciences Oncology 1 Phase 3 $274M 1
IDYA IDEAYA Biosciences Oncology 2 NDA Submitted $2.65B 15
IBRX ImmunityBio Infectious DiseaseOncology 1 Approved $6.66B 17
IMNM Immunome Oncology Rare 1 NDA Submitted $2.03B 9
KAPA Kairos Pharma Oncology 1 Phase 2 $1.9M 12
KZIA Kazia Therapeutics NeurologyOncology Rare 2 Phase 2 $60.7M 13
GLUE Monte Rosa Therapeutics CardiovascularDermatology+3 Rare 1 Phase 2 $775M 7
OLMA Olema Pharmaceuticals Oncology 2 Phase 3 $633M 3
OKUR OnKure Therapeutics Oncology 1 Preclinical $104M 2
ORIC Oric Pharmaceuticals Oncology 1 Phase 3 $831M 5
PMVP PMV Pharmaceuticals Oncology 1 Phase 2 $92.2M 7
PRLD Prelude Therapeutics HematologyOncology Rare 1 Phase 1 $266M 3
RLAY Relay Therapeutics DermatologyOncology Rare 1 Approved $3.64B 4